ZEAL
NASDAQZealand Pharma A/S
News · 26 weeks59-27%
2026-04-192026-10-11
Mix2890d
- Other24(86%)
- Earnings2(7%)
- M&A1(4%)
- Dividends1(4%)
Latest news
25 items- PRGenerate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesCollaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will receive $30M upfront, up to $35M in early preclinical milestones, and a total of up to nearly $1.2B in milestones, plus tiered royalties for two initial programs, with an option to add a third The agreement will broaden Zealand Pharma’s modality capabilities beyond peptides while extending The Generate Platform into obesity and other metabolic diseases SOMERVILLE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced a m
- PRZealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesPress release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functionsGenerate will receive USD 30 million up-front, up to USD 35 million in early preclinical milestones, and a total of nearly USD 1.2 billion in milestones, plus tiered royalties for two initial programs, with an option to add a thirdThe agreement will broaden Zealand Pharma’s modality capabilities beyond peptides
- PRZealand Pharma announces opening of new Research Hub in Cambridge, MassachusettsPress release – No. 19 / 2026 Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts Builds on the Metabolic Frontier 2030 strategy, advancing its ambition to become a leader in obesity and metabolic healthRibbon-cutting ceremony marks the official opening of the Company’s primary U.S. address, expanding Zealand Pharma’s global research platform Copenhagen, Denmark, and Boston, Massachusetts, September 30, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today celebrated the opening of its new research hub at 35 CambridgePark Drive in Cambridge, Massachusetts, with a ribbon-cutting c
- PRZealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetesCompany announcement – No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a population in which weight loss is typically more challenging.1Detailed results from the Phase III trial indicate survodutide improves key markers of cardiometabolic health, including a reduction of u
- PRZealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & EndocrinologyPress release – No. 18 / 2026 Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology Treatment with petrelintide was associated with clinically meaningful, double-digit weight loss, with a gastrointestinal tolerability profile comparable to placeboTreatment was associated with significant improvements in cardiometabolic disease risk factors, including reductions in pulse rate, high-sensitivity C-reactive protein and waist circumferenceAdditional results from the ZUPREME-1 study will be presented in an oral presentation at EASD 2026 on September 30 at 3:30pm CESTA
- PRZealand Pharma - Transactions related to share buy-back program (week 39, 2026)Company announcement No. 50 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) Copenhagen, Denmark, September 28, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the "Program") for week 39 (September 21 - September 25, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Reference is made to company announcement no
- PRZealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesityPress release – No. 17 / 2026 Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity The Phase 3 initiation marks a defining step toward establishing petrelintide as a future first-choice therapy for millions of people living with overweight or obesityThe global Phase 3a ZUPREME program consists of three trials, designed to support marketing applications for petrelintide monotherapy in chronic weight managementThe Phase 3a program builds on positive Phase 2 results, which demonstrated double-digit weight loss with a tolerability profile largely comparable to placebo, supporting petrelintide’s potential to rede
- PRZealand Pharma - Transactions related to share buy-back program (week 38, 2026)Company announcement No. 49 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) Copenhagen, Denmark, September 21, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the "Program") for week 38 (September 14 - September 18, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Reference is made to company announcement no
- PRZealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndromePress release – No. 16 / 2026 Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome The CHMP of the European Medicines Agency has recommended the approval of Zeydovio™ (glepaglutide) for the treatment of short bowel syndromeThe positive CHMP opinion marks the first major advancement in short bowel syndrome treatment in Europe in more than a decadeZeydovio’s™ evidenced efficacy combined with its simple delivery, positions it as a transformative therapy for people living with short bowel syndromeTwo thirds of patients treated with glepaglutide achieved a clinical response of at least a 20% reduction in weekly parenteral support
- PRElvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 DiabetesThe company plans to advance the licensed GLP-1/gastrin dual-agonist peptide portfolio from Zealand Pharma as a disease-modifying therapy to regenerate and protect endogenous beta-cell mass in patients with type 1 diabetes. Elvinix Inc., a biopharmaceutical company developing a regenerative, disease-modifying therapy for type 1 diabetes (T1D), today announced an exclusive license agreement with Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL), granting Elvinix the rights to develop and commercialize Zealand’s GLP-1/gastrin dual-agonist peptide portfolio. Approximately 9.5 million people worldwide live with T1D, a number that rises each year.(1) Elvinix is developing a novel, disease-modifyi
- PRZealand Pharma - Transactions related to share buy-back program (week 37, 2026)Company announcement No. 48 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) Copenhagen, Denmark, September 14, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the "Program") for week 37 (September 7 - September 11, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Reference is made to company announcement no.
- PRZealand Pharma increases its share capital as a result of the exercise of employee warrantsCompany announcement – No. 47 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 10, 2026 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 31,247 divided into 31,247 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under one of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme. Each wa
- PRZealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare ConferencePress release – No. 15 / 2026 Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference Copenhagen, Denmark, September 9, 2026 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Wednesday, September 16, 2026, at 11:30am EDT (5:30pm CEST). A live audio webcast of the fireside chat will be available at https://event.webcasts.com/starthere.jsp?ei=1773811&tp_key=f2cb5f5403&tp_special=8, and accessible through the compa
- PRZealand Pharma - Transactions related to share buy-back program (week 36, 2026)Company announcement No. 46 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) Copenhagen, Denmark, September 7, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the "Program") for week 36 (August 31 - September 4, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Reference is made to company announcement no. 15
- PRCorrection: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)Company announcement No. 45 / 2026 Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, September 2, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby corrects information regarding the dates for the reported transactions related to its share buy-back program (the "Program") for week 35 (August 24 – August 28, 2026), initially published in company announcement no. 44 / 2026 on August 31, 2026, as the correct dates for week 35 have now been added to the report on transactions for this period in the reporting tab
- PRZealand Pharma - Transactions related to share buy-back program (week 35, 2026)Company announcement No. 44 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, August 31, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the "Program") for week 35 (August 24 - August 28, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Reference is made to company announcement no. 15 / 20
- PRTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCompany announcement – No. 43 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, August 28, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). About Zealand PharmaZeal
- PRZealand Pharma – Notification of holding of treasury sharesCompany announcement – No. 42 / 2026 Zealand Pharma – Notification of holding of treasury shares Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports its notification pursuant to Section 31 of the Danish Capital Markets Act relating to its holding of treasury shares. As of 21 August 2026, the Company holds nominally 3,597,842 treasury shares, corresponding to 5.03% of the total share capital and 5.03% of the total voting rights in Zealand Pharma. In accordance with Section 85 of the Danish Companies Act, the Company cannot exercise a
- PRZealand Pharma - Transactions related to share buy-back program (week 34, 2026)Company announcement No. 41 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the "Program") for week 34 (August 17 - August 21, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Reference is made to company announcement no. 15 / 20
- PRZealand Pharma - Transactions related to share buy-back program (week 33, 2026)Company announcement No. 40 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 33, 2026) Copenhagen, Denmark, August 17, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the "Program") for week 33 (August 10 - August 14, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Reference is made to company announcement no. 15 / 20
- PRZealand Pharma Announces Financial Results for the First Half of 2026Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all fronts of our Metabolic Frontier 2030 strategy. Announced decision to advance petrelintide into Phase 3 trials in H2 2026 following positive Phase 2 results, demonstrating double-digit weight loss with a tolerability profile largely comparable to placebo, supporting its potential to redefine the weight management experience for people living with obesity or overweight.Boehringer Ingelheim presented positive results from the SYNCHRONIZETM-1 and SYNCHRONIZE
- PRZealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertideCompany announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic interests related to rusfertide, including royalty rights on the potential future global net sales of rusfertide.The agreement unlocks value from a non-core royalty entitlement for redeployment to Zealand Pharma’s key strategic priorities. Copenhagen, Denmark, August 12, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that it has entered into a ro
- PRZealand Pharma - Transactions related to share buy-back program (week 32, 2026)Company announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the "Program") for week 32 (August 3 - August 7, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Reference is made to company announcement no. 15 / 2026
- PRZealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial resultsPress Release – No. 14 / 2026 Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results Copenhagen, Denmark, August 6, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on August 13, 2026, at 2:00 pm CEST (8:00 am ET) following the announcement of financial results for the second quarter / first six months of 2026. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will
- PRZealand Pharma - Transactions related to share buy-back program (week 31, 2026)Company announcement No. 36 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 31, 2026) Copenhagen, Denmark, August 3, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the "Program") for week 31 (July 27 - July 31, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, "MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Reference is made to company announcement no. 15 / 2026 da
ZEAL FAQ
7 questionsWhat does Zealand Pharma A/S do?
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has...Where does ZEAL stock trade?
Zealand Pharma A/S (ZEAL) is listed on NASDAQ.What sector and industry is ZEAL in?
Zealand Pharma A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zealand Pharma A/S go public?
Zealand Pharma A/S (ZEAL) completed its IPO in 2017.What are analysts saying about ZEAL?
Zealand Pharma A/S has had 4 recent analyst actions on file. The most recent action was from Berenberg: Buy on 2024-03-05.What companies are similar to ZEAL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ZEAL side-by-side with any of them on Quantisnow.How can I track ZEAL on Quantisnow?
Quantisnow aggregates Zealand Pharma A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZEAL to receive live email and push alerts on every new disclosure.